Alpha-fetoprotein peptides and uses thereof
View Patent ↗Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form of a pharmaceutically acceptable scaffold, such as a polycyclic hydrocarbon to which is attached the necessary amino acid structures for biological and/or chemical activity. The modulators of the invention are distinguished in one aspect over previous compounds in that they are orally active, and therefore do not have to be injected into the patient. The compositions and methods are useful for reducing estrogen-stimulated growth of cells, and treating or preventing cancer, such as breast cancer. The treatment or prevention methods can include the use of tamoxifen therapy in combination with the peptide therapy.
1. An alpha-fetoprotein peptide consisting of the amino acid sequence of EKTOVNOGN (SEQ ID NO:1), wherein said peptide modulates cell proliferation.
2. An alpha-fetoprotein peptide consisting of the amino acid sequence of EKTOVNOGN (SEQ ID NO:1), wherein the lysine residue is D-lysine or acetylated L-lysine.
3. The alpha-fetoprotein peptide of claim 1 or 2 , wherein said peptide is cyclic.
4. A fusion protein comprising a breast cancer targeting moiety and a light-generating polypeptide moiety, wherein said breast cancer targeting moiety comprises an alpha-fetoprotein peptide consisting of the amino acid sequence of EKTOVNOGN (SEQ ID NO:1).
5. The fusion protein of claim 4 , wherein said light-generating polypeptide moiety is responsive to phosphorylation changes at or near the breast cancer site.
6. A method of treating breast cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the alpha-fetoprotein peptide of claim 1 or 2 , wherein said peptide modulates cell proliferation such that breast cancer is treated.
7. The method of claim 6 , wherein said alpha-fetoprotein peptide is administered orally.
8. The method of claim 6 , further comprising co-administering a therapeutically effective amount of a chemotherapeutic agent.
9. The method of claim 8 , wherein said chemotherapeutic agent is tamoxifen.
10. The method of claim 6 , wherein said alpha-fetoprotein peptide is cyclic.